Why UK for Biomed?
The UK pharmaceutical industry has discovered or developed more than a fifth of the world’s 100 top selling medicines. The UK has the largest and most mature biopharmaceutical product pipeline in Europe, second only to the United States.
The UK has a strong medical device and diagnostics sector, which benefits from international companies running R&D bases and operations there.The National Health Service is the principle purchaser in the UK and one of the largest health systems in the world. The NHS represents over 700 organizations and works to consolidate policies and practices on development, adoption and purchase of new technologies.
The new UK Government Office for Life Sciences provides a business-led vision for the medicine and healthcare sector and is aiming to drive innovation forward in the development of the next generation of disease prevention, diagnosis and treatment. Strong collaboration between industry, academia, the NHS and Government is core to the UK maintaining and growing R&D in the life sciences industry, as well as delivering benefits for patients around the world.
Biomed
///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
What could this mean for you?
• Access to government international collaboration programs supporting R&D projects and tech cooperation
• Information and contacts regarding specific technology and business incentive programmes
• Cooperation with the UK's multinational pharma companies/ with Israel's leading medtech, pharma and device companies
• Clinical trials in world renowned medical institutions, with leading academic medical researchers
• Structured regulation processes in a supportive atmosphere recognized all over Europe
• Beta site testing in one of the world largest national health services organizations
• Manufacturing, marketing and distribution globally
Why Israel for Biomed?
Israel has in recent years turned into a life sciences powerhouse — the world leader in the number of medical device patents per capita, and second in biopharmaceuticals. Israel has a strong talent pool, and has been acknowledged as a world leader in the quality of scientific research institutions.
Over the years, medical devices developed in Israel helped transform healthcare systems around the world. Among them, the Pillcam (the first miniature ingested camera developed by Given Imaging), the closed cell stent design facilitating blood flow to the heart by Medinol Surgical, and sealant Quixil developed by Omrix and acquired by Ethicon MediGuide. In pharmaceuticals, Israel can also boast impressive achievements, among which are: Doxil, a chemotherapy for ovarian cancer, developed at the Hadassah Medical Center and was sold to J&J; Teva/Weizmann Institute developed Copaxone, the multiple sclerosis treatment; Azilect, a Parkinson’s Disease therapy, was developed by Teva based on research at the Technion in Haifa; Exelon, a drug for the treatment of Alzheimer’s originated at the Hebrew University and was developed and marketed by Novartis.
Today, one out of six prescriptions dispensed over the pharmacy counter in the UK is supplied by Israel's Teva Pharmaceuticals whose presence in the United Kingdom includes science cooperation and manufacturing.
///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
We connect leading Biomed innovators, medtech and pharma companies and medical researchers from the UK and Israel to access new business opportunities in life sciences and address global health challenges